Human Resources News - The HR Digest
Oct 28, 2024 · The HR Digest covers the latest news and insights from the human resource industry, including labor disputes, wage increases, layoffs, and more. Find out what's happening in the world of HR with articles on topics such as Stellantis-UAW, TGI …
HR & Workplace News & Trends - SHRM
Find out the latest news and insights on human resources and workplace issues from SHRM, the world's largest HR professional association. Explore topics such as ageism, health care costs,...
HRMorning - HR News and Insights
HRMorning covers the latest HR and employment law news for small-to-medium-sized businesses. Find out how to navigate workforce challenges, leverage HR tech, and avoid legal pitfalls with actionable insights and tips.
HR+ - Fast Company
Find the latest HR+ news from Fast company. See related business and technology articles, photos, slideshows and videos.
HR News and Analysis | HR Dive
HR Dive covers the latest trends and topics in human resources, such as compliance, talent, learning, compensation and benefits, diversity and inclusion, and more. Find out how HR can adapt...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
Sep 17, 2024 · Kisqali (ribociclib) is a CDK4/6 inhibitor that reduces the risk of recurrence by 25% in people with HR+/HER2- stage II and III EBC at high risk of recurrence. The approval is based on the NATALEE trial results and includes patients with node-negative disease.
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Sep 17, 2024 · The FDA has approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor (AI) for the treatment of patients with hormone receptor–positive, HER2-negative stage II and III early breast...
Talent News - HR Dive
6 days ago · HR Dive covers the latest news and insights on talent management, employee engagement, diversity, equity and inclusion, and more. Find out how AI, skills shortages, benefits, and labor policies...
Understanding HR+ or HER2– breast cancer diagnosis - Medical News Today
Feb 23, 2024 · HR+ or HER2– is the most common type of breast cancer, with hormone receptors and low HER2 levels. Learn about the diagnosis, treatment options, and survival rates of this condition.
Targeted Agents Expand the HR+/HER2– Metastatic Breast
Mar 9, 2024 · Learn about the latest developments in second-line therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Find out how CDK4/6 inhibitors, SERDs, and...